Compounded semaglutide

Is compounded semaglutide legit? How to vet the seller before you pay

FDA has been unusually specific about compounded semaglutide. The agency has named the wrong ingredient, the wrong dose and the wrong label as problems it has actually seen, and each one gives you a question to put to a seller.

Wegovy injection 0.25–2.4 mg: $349 per 28-day fill after any introductory offer. The comparison excludes oral Wegovy and HD 7.2 mg, which costs $399 per fill. Eligibility and other terms apply. All comparison amounts use 30.4375 days: each 28-day brand fill × 30.4375 ÷ 28. These are cost equivalents, not checkout charges. Manufacturer terms (checked October 2026).

What 2025 left standing²

Semaglutide entered FDA’s shortage list twice, because it is sold as two injections: Wegovy in March 2022 and Ozempic in August 2022. Those listings are what let pharmacies copy it in volume. On 21 February 2025 FDA issued a declaratory order finding the shortage resolved. Compounders sued three days later in their own case, 4:25-cv-00174, and on 24 April 2025 the court declined to pause the order. FDA then confirmed that the grace period for state-licensed pharmacies was over, and gave outsourcing facilities until 22 May 2025.

Semaglutide is not on the 503B bulks list, so large outsourcing facilities cannot make it from bulk powder today. A state-licensed pharmacy can still compound it for an individual patient. It cannot routinely turn out what amounts to a copy of Wegovy or Ozempic unless the prescriber documents a significant difference that this patient needs. The dated history, docket by docket, is on the legal-status page.

Ask which semaglutide it is¹

This question is unique to semaglutide. FDA says some compounders have used salt forms, semaglutide sodium and semaglutide acetate, which are “different active ingredients than are used in the approved drugs.” The agency has no information that they behave like the approved ingredient and knows of no lawful basis for compounding with them. A reputable seller can tell you the active ingredient printed on its pharmacy’s label. A salt form on that label, or a seller who will not say, is a reason to walk away. What a compounded vial may contain.

B12 is not a license²

Many sellers call their product “personalized” because it adds vitamin B12, as if the extra ingredient made it a different drug. FDA used semaglutide as its own example of why that does not follow. A semaglutide and B12 injection can still count as essentially a copy when it is given the same way as the approved products and both ingredients sit within 10% of their commercial strengths. A documented clinical reason for you in particular is what matters, not the add-in. What B12, B6 and glycine are doing in the vial.

The prescriber and the pharmacy¹

Semaglutide is prescription-only however it is made. A real program has a clinician licensed in your state review your history and keep the right to refuse. That is step three of the process. A site that bills and ships with no screening fails FDA’s own list of telehealth red flags.

The pharmacy should have a name you can check. Every state board of pharmacy publishes a license lookup, and outsourcing facilities appear on FDA’s registered outsourcing facility list with their inspection history. That lookup matters because FDA has found fraudulent compounded semaglutide with false labels. Some named pharmacies that do not exist. Others used a licensed pharmacy’s name when that pharmacy never made the product. Compare the name and address on your vial with the license record, and treat spelling mistakes on the label as a warning sign.

Dosing instructions are part of the check³

Semaglutide starts small. The Wegovy label opens at 0.25 mg once weekly for four weeks, so the first doses from a multi-dose vial are tiny volumes. FDA has received adverse-event reports, some requiring hospitalization, that may be linked to dosing errors with compounded injectable semaglutide. Patients measured the wrong amount, and in some cases health care professionals miscalculated it.¹ A trustworthy seller tells you the vial’s concentration and how your prescribed dose translates to a mark on the syringe. Follow the pharmacy label and your prescriber, and check the arithmetic with the units tool or units and milligrams.

Counterfeit pens are a separate problem¹

FDA is aware of counterfeit Ozempic sold in the US. Those are fake branded pens, which may hold the wrong ingredient or none at all. Wegovy injection 0.25–2.4 mg has an equivalent calendar-month cost of $379.38 ($349 per 28-day fill) once an introductory $199 rate for the first two fills ends, according to its manufacturer terms. A “brand-name” pen offered well below that, outside a licensed pharmacy, fits FDA’s warning about prices that seem too good to be true. Vials sold “for research use only” are another route FDA has named: it has warned companies selling semaglutide that way directly to consumers. What research-labeled vials are, and FDA’s BeSafeRx guide to online pharmacies.

Warning letters, already matched⁴

FDA publishes its warning letters, but its search box does not reliably find them. This index screens every listed semaglutide seller against the complete set, matching on the company behind the site because one operator often runs several brands. 41 of 410 sellers hold at least one letter, and each is named only where the letter cites that seller’s own domain. The list is on the trust page. Every seller here also sells through a prescriber, and every price is read on the seller’s own checkout and dated. What stays with you is your own order: the pharmacy it is routed to, and that pharmacy’s license in your state. How sellers are verified →